Physician profile
Algert Rista
NPI 1417659459
$2,622.47
in general payments reported to CMS, 2019-2025
15 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $258 · 2024: $1,079 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $866.20 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $341.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $274.52 | 2024-2025 | Otezla, Krystexxa, Repatha |
| Lilly USA, LLC | $271.93 | 2024-2025 | Mounjaro, Zepbound, Taltz |
| Abbvie INC. | $263.19 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $132.52 | 2024 | Voquezna |
| Ucb, INC. | $124.99 | 2024 | Bimzelx |
| Atricure, INC. | $99.82 | 2025 | Synergy Ablation System |
| Lundbeck LLC | $79.01 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.83 | 2025 | Xifaxan |
| Novo Nordisk INC | $31.87 | 2025 | Ozempic, Wegovy |
| Astellas Pharma US INC | $22.04 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $19.99 | 2024 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.26 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Algert Rista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.